Währungen / AKRO
AKRO: Akero Therapeutics Inc
46.73
USD
0.21
(0.45%)
Der Wechselkurs von AKRO hat sich für heute um -0.45% verändert. Im Laufe des Tages wurde das Instrument von einem Tief von 46.02 bis zu einem Hoch von 47.34 gehandelt.
Verfolgen Sie die Akero Therapeutics Inc-Dynamik. Mit Echtzeit-Kursen können Sie schnell auf Marktveränderungen reagieren. Indem Sie zwischen verschiedenen Zeitrahmen wechseln, können Sie Kurstrends und -dynamik nach Minuten, Stunden, Tagen, Wochen und Monaten verfolgen. Nutzen Sie diese Informationen, um Marktveränderungen vorherzusagen und fundierte Handelsentscheidungen zu treffen.
- M5
- M15
- M30
- H1
- H4
- D1
- W1
- MN
AKRO News
- Has Akero Therapeutics (AKRO) Outpaced Other Medical Stocks This Year?
- Does Akero Therapeutics (AKRO) Have the Potential to Rally 59.14% as Wall Street Analysts Expect?
- RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study
- Akero Therapeutics: Reversing My Contrarian Buy Rating To A Contrarian Sell Rating (AKRO)
- Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus
- Akero Therapeutics CEO Cheng sells $1.46 million in stock
- Akero Therapeutics COO Young sells $597k in shares
- Akero therapeutics director Henderson sells $142k in shares
- Are Medical Stocks Lagging Akero Therapeutics (AKRO) This Year?
- Akero Therapeutics stock strengthened as Morgan Stanley reiterates Overweight rating
- Janus Henderson Global Life Sciences Diversified ADR Managed Account Q2 2025 Commentary
- Akero Therapeutics stock initiated with Buy rating at TD Cowen on MASH potential
- Akero Therapeutics stock initiated with Buy rating at TD Cowen on MASH treatment potential
- This AeroVironment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Akero Therapeutics (NASDAQ:AKRO), Apartment Inv & Mgmt (NYSE:AIV)
- Janus Henderson Global Life Sciences Fund Q2 2025 Commentary (Mutual Fund:JAGLX)
- Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect
- Amarin Gears Up to Report Q2 Earnings: Here's What to Expect
- Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
- VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales
- Altimmune: Potential Tough Road Ahead Amid Fierce Competition (Rating Downgrade) (ALT)
- Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth?
- Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect
- RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure
- FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo
Tagesspanne
46.02
47.34
Jahresspanne
21.34
58.40
- Vorheriger Schlusskurs
- 46.94
- Eröffnung
- 47.01
- Bid
- 46.73
- Ask
- 47.03
- Tief
- 46.02
- Hoch
- 47.34
- Volumen
- 1.002 K
- Tagesänderung
- -0.45%
- Monatsänderung
- -3.49%
- 6-Monatsänderung
- -2.65%
- Jahresänderung
- 73.14%
31 August, Sonntag